142 related articles for article (PubMed ID: 38778814)
1. Co-rotating twin screw process for continuous manufacturing of solid crystal suspension: A promising strategy to enhance the solubility, permeation and oral bioavailability of Carvedilol.
Navti PD; Fernandes G; Soman S; Nikam AN; Kulkarni S; Birangal SR; Dhas N; Shenoy GG; Rao V; Koteshwara KB; Mutalik S
F1000Res; 2023; 12():1438. PubMed ID: 38778814
[No Abstract] [Full Text] [Related]
2. Carvedilol nano lipid carriers: formulation, characterization and in-vivo evaluation.
Mishra A; Imam SS; Aqil M; Ahad A; Sultana Y; Ameeduzzafar ; Ali A
Drug Deliv; 2016 May; 23(4):1486-94. PubMed ID: 26978072
[TBL] [Abstract][Full Text] [Related]
3. Dual Activity of Hydroxypropyl-β-Cyclodextrin and Water-Soluble Carriers on the Solubility of Carvedilol.
Zoghbi A; Geng T; Wang B
AAPS PharmSciTech; 2017 Nov; 18(8):2927-2935. PubMed ID: 28432614
[TBL] [Abstract][Full Text] [Related]
4. Carboxylated mesoporous carbon microparticles as new approach to improve the oral bioavailability of poorly water-soluble carvedilol.
Zhang Y; Zhi Z; Li X; Gao J; Song Y
Int J Pharm; 2013 Sep; 454(1):403-11. PubMed ID: 23850816
[TBL] [Abstract][Full Text] [Related]
5. Comparative study on stabilizing ability of food protein, non-ionic surfactant and anionic surfactant on BCS type II drug carvedilol loaded nanosuspension: Physicochemical and pharmacokinetic investigation.
Geng T; Banerjee P; Lu Z; Zoghbi A; Li T; Wang B
Eur J Pharm Sci; 2017 Nov; 109():200-208. PubMed ID: 28811130
[TBL] [Abstract][Full Text] [Related]
6. Novel scheme for rapid synthesis of hollow mesoporous silica nanoparticles (HMSNs) and their application as an efficient delivery carrier for oral bioavailability improvement of poorly water-soluble BCS type II drugs.
Li T; Geng T; Md A; Banerjee P; Wang B
Colloids Surf B Biointerfaces; 2019 Apr; 176():185-193. PubMed ID: 30616109
[TBL] [Abstract][Full Text] [Related]
7. Development and optimization of carvedilol orodispersible tablets: enhancement of pharmacokinetic parameters in rabbits.
Aljimaee YH; El-Helw AR; Ahmed OA; El-Say KM
Drug Des Devel Ther; 2015; 9():1379-92. PubMed ID: 25834396
[TBL] [Abstract][Full Text] [Related]
8. Development and evaluation of carvedilol-loaded transdermal drug delivery system: In-vitro and in-vivo characterization study.
Kshirsagar SJ; Bhalekar MR; Mohapatra SK
Drug Dev Ind Pharm; 2012 Dec; 38(12):1530-7. PubMed ID: 22356303
[TBL] [Abstract][Full Text] [Related]
9. Novel carvedilol paediatric nanomicelle formulation: in-vitro characterization and in-vivo evaluation.
Wegmann M; Parola L; Bertera FM; Taira CA; Cagel M; Buontempo F; Bernabeu E; Höcht C; Chiappetta DA; Moretton MA
J Pharm Pharmacol; 2017 May; 69(5):544-553. PubMed ID: 27431770
[TBL] [Abstract][Full Text] [Related]
10.
Krishna VM; Kumar VB; Dudhipala N
Pharm Nanotechnol; 2020; 8(3):207-224. PubMed ID: 32416685
[TBL] [Abstract][Full Text] [Related]
11. Development of optimized self-nano-emulsifying drug delivery systems (SNEDDS) of carvedilol with enhanced bioavailability potential.
Singh B; Khurana L; Bandyopadhyay S; Kapil R; Katare OO
Drug Deliv; 2011 Nov; 18(8):599-612. PubMed ID: 22008038
[TBL] [Abstract][Full Text] [Related]
12. Fabrication of novel GMO/Eudragit E100 nanostructures for enhancing oral bioavailability of carvedilol.
Patil SS; Roy K; Choudhary B; Mahadik KR
Drug Dev Ind Pharm; 2016 Aug; 42(8):1300-7. PubMed ID: 26651381
[TBL] [Abstract][Full Text] [Related]
13. Effect of particle size on oral absorption of carvedilol nanosuspensions: in vitro and in vivo evaluation.
Liu D; Pan H; He F; Wang X; Li J; Yang X; Pan W
Int J Nanomedicine; 2015; 10():6425-34. PubMed ID: 26508852
[TBL] [Abstract][Full Text] [Related]
14. Solubility enhancement and physicochemical characterization of carvedilol solid dispersion with Gelucire 50/13.
Potluri RH; Bandari S; Jukanti R; Veerareddy PR
Arch Pharm Res; 2011 Jan; 34(1):51-7. PubMed ID: 21468915
[TBL] [Abstract][Full Text] [Related]
15. Tracking of crystalline-amorphous transition of carvedilol in rotary spun microfibers and their formulation to orodispersible tablets for in vitro dissolution enhancement.
Szabó P; Sebe I; Stiedl B; Kállai-Szabó B; Zelkó R
J Pharm Biomed Anal; 2015 Nov; 115():359-67. PubMed ID: 26280924
[TBL] [Abstract][Full Text] [Related]
16. Development of carvedilol transdermal patches: evaluation of physicochemical, ex vivo and mechanical properties.
Gannu R; Vishnu YV; Kishan V; Rao YM
PDA J Pharm Sci Technol; 2008; 62(6):391-401. PubMed ID: 19634343
[TBL] [Abstract][Full Text] [Related]
17. Fabrication of carvedilol nanosuspensions through the anti-solvent precipitation-ultrasonication method for the improvement of dissolution rate and oral bioavailability.
Liu D; Xu H; Tian B; Yuan K; Pan H; Ma S; Yang X; Pan W
AAPS PharmSciTech; 2012 Mar; 13(1):295-304. PubMed ID: 22246736
[TBL] [Abstract][Full Text] [Related]
18. Investigations of a novel self-emulsifying osmotic pump tablet containing carvedilol.
Wei L; Li J; Guo L; Nie S; Pan W; Sun P; Liu H
Drug Dev Ind Pharm; 2007 Sep; 33(9):990-8. PubMed ID: 17891586
[TBL] [Abstract][Full Text] [Related]
19. In silico-in vitro-in vivo studies of experimentally designed carvedilol loaded silk fibroin-casein nanoparticles using physiological based pharmacokinetic model.
Kumar S; Singh SK
Int J Biol Macromol; 2017 Mar; 96():403-420. PubMed ID: 28013012
[TBL] [Abstract][Full Text] [Related]
20. Preparation, Characterization, and Selection of Optimal Forms of (S)-Carvedilol Salts for the Development of Extended-Release Formulation.
Zhang Q; Huang B; Xue H; Lin Z; Zhao J; Cai Z
Mol Pharm; 2021 Jun; 18(6):2298-2310. PubMed ID: 34032449
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
